Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000112182 | SCV000300018 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2016-09-08 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000112182 | SCV000325754 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000574583 | SCV000661042 | pathogenic | Hereditary cancer-predisposing syndrome | 2016-06-08 | criteria provided, single submitter | clinical testing | The c.3779delT pathogenic mutation, located in coding exon 9 of the BRCA1 gene, results from a deletion of one nucleotide at nucleotide position 3779, causing a translational frameshift with a predicted alternate stop codon. This alteration has been previously reported in multiple high-risk individuals and families with breast and/or ovarian cancer (Shattuck-Eidens D et al. JAMA 1995 Feb; 273(7):535-41; Stavropoulou AV et al. PLoS ONE 2013 Mar; 8(3):e58182; Kluska A et al. BMC Med Genomics 2015 May; 8:19; Gaj P et al. Fam. Cancer 2012 Dec;11(4):623-8). Of note, this alteration is also designated as c.3777delT and 3896delT in the published literature. In addition to the clinical data presented in the literature, since frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |
Institute of Medical Genetics and Applied Genomics, |
RCV001268404 | SCV001447313 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Breast Cancer Information Core |
RCV000112182 | SCV000144877 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2002-05-29 | no assertion criteria provided | clinical testing |